Michel Eichelbaum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michel Eichelbaum has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Christine Fischer
Department of Internal Medicine II, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria
3 shared publications - Gerd Mikus
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany
3 shared publications Hermann Wisser
Dr. Margarete Fischer‐Bosch‐Institut für Klinische Pharmakologie and the Abteilung für Klinische Chemie/Labormedizin, Robert‐Bosch‐Krankenhaus Stuttgart Germany
2 shared publications- Matthias Schwab
Dr. Margarete Fischer‐Bosch Institute of Clinical Pharmacology Stuttgart Germany
2 shared publications - Thomas Mürdter
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tuebingen, Tuebingen, Germany
2 shared publications - Ute Hofmann
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
2 shared publications
Latest Publications
- Open Access
- 27 August 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (19) , e202500426
Cytotoxicity of Atropisomeric [1,1′‐Binaphthalene]‐2,2′‐Diamines (BINAM) and Analogs in Human Cancer Cells: Enantioselectivity, Structure–Activity Relationships, and Mechanism
Binaphthyls usually serve as key chiral ligands in catalysts for asymmetric syntheses, having been reported in thousands of published reactions. Herein, the discovery that atropisomeric (R)‐[1,1′‐binaphthalene]‐2,2′‐diamine (R‐BINAM, 1(R)) is a moderately potent spindle poison, causing antiproliferation, depolymerization of microtubules, multipolar spindles, pericentriolar material (PCM) fragmentation, mitotic catastrophe, multinucleated cells, and apoptosis in cancer and normal human cell lines, is reported. Furthermore, the resulting abnormalities resemble those induced by microtubule‐depolymerizing agents (MDAs) such as colchicine. In contrast, the enantiomer S‐BINAM (1(S)) was inactive in all biological assays. Additionally, the structure–activity relationships of a selection of R‐ and S‐BINAM derivatives with key structural differences have been studied; these studies show the same enantiomeric trend as with R‐BINAM and provide insight into the structural requirements for the antiproliferative activity of this compound class. These findings should be useful for the development of more selective spindle poisons, especially due to the natural rigidity of binaphthyls and their scaffold that allows for various modifications.
- 27 August 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (19) , e202500426
Open AccessCytotoxicity of Atropisomeric [1,1′‐Binaphthalene]‐2,2′‐Diamines (BINAM) and Analogs in Human Cancer Cells: Enantioselectivity, Structure–Activity Relationships, and Mechanism
Binaphthyls usually serve as key chiral ligands in catalysts for asymmetric syntheses, having been reported in thousands of published reactions. Herein, the discovery that atropisomeric (R)‐[1,1′‐binaphthalene]‐2,2′‐diamine (R‐BINAM, 1(R)) is a moderately potent spindle poison, causing antiproliferation, depolymerization of microtubules, multipolar spindles, pericentriolar material (PCM) fragmentation, mitotic catastrophe, multinucleated cells, and apoptosis in cancer and normal human cell lines, is reported. Furthermore, the resulting abnormalities resemble those induced by microtubule‐depolymerizing agents (MDAs) such as colchicine. In contrast, the enantiomer S‐BINAM (1(S)) was inactive in all biological assays. Additionally, the structure–activity relationships of a selection of R‐ and S‐BINAM derivatives with key structural differences have been studied; these studies show the same enantiomeric trend as with R‐BINAM and provide insight into the structural requirements for the antiproliferative activity of this compound class. These findings should be useful for the development of more selective spindle poisons, especially due to the natural rigidity of binaphthyls and their scaffold that allows for various modifications.
- 25 July 2015
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 407 (24) , 7497-7502
Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS
Tamoxifen is a mainstay in the treatment of estrogen receptor-positive breast cancer and is metabolized to more than 30 different compounds. Little is known about in vivo concentrations of estrogenic metabolites E-metabolite E, Z-metabolite E, and bisphenol and their relevance for tamoxifen efficacy. Therefore, we developed a highly sensitive HPLC-ESI-MS/MS quantification method for tamoxifen metabolites bisphenol, E-metabolite E, and Z-metabolite E as well as for the sex steroid hormones estradiol, estrone, testosterone, androstenedione, and progesterone. Plasma samples were subjected to protein precipitation followed by solid phase extraction. Upon derivatization with 3-[(N-succinimide-1-yl)oxycarbonyl]-1-methylpyridinium iodide, all analytes were separated on a sub-2-μm column with a gradient of acetonitrile in water with 0.1 % of formic acid. Analytes were detected on a triple-quadrupole mass spectrometer with positive electrospray ionization in the multiple reaction monitoring mode. Our method demonstrated high sensitivity, accuracy, and precision. The lower limits of quantification were 12, 8, and 25 pM for bisphenol, E-metabolite E, and Z-metabolite E, respectively, and 4 pM for estradiol and estrogen, 50 pM for testosterone and androstenedione, and 25 pM for progesterone. The method was applied to plasma samples of postmenopausal patients taken at baseline and under tamoxifen therapy. Graphical Abstract Sample preparation and derivatization for highly sensitive quantification of estrogenic tamoxifen metabolites and steroid hormones by HPLC-MS/MS Sample preparation and derivatization for highly sensitive quantification of estrogenic tamoxifen metabolites and steroid hormones by HPLC-MS/MS
- 25 July 2015
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 407 (24) , 7497-7502
Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS
Tamoxifen is a mainstay in the treatment of estrogen receptor-positive breast cancer and is metabolized to more than 30 different compounds. Little is known about in vivo concentrations of estrogenic metabolites E-metabolite E, Z-metabolite E, and bisphenol and their relevance for tamoxifen efficacy. Therefore, we developed a highly sensitive HPLC-ESI-MS/MS quantification method for tamoxifen metabolites bisphenol, E-metabolite E, and Z-metabolite E as well as for the sex steroid hormones estradiol, estrone, testosterone, androstenedione, and progesterone. Plasma samples were subjected to protein precipitation followed by solid phase extraction. Upon derivatization with 3-[(N-succinimide-1-yl)oxycarbonyl]-1-methylpyridinium iodide, all analytes were separated on a sub-2-μm column with a gradient of acetonitrile in water with 0.1 % of formic acid. Analytes were detected on a triple-quadrupole mass spectrometer with positive electrospray ionization in the multiple reaction monitoring mode. Our method demonstrated high sensitivity, accuracy, and precision. The lower limits of quantification were 12, 8, and 25 pM for bisphenol, E-metabolite E, and Z-metabolite E, respectively, and 4 pM for estradiol and estrogen, 50 pM for testosterone and androstenedione, and 25 pM for progesterone. The method was applied to plasma samples of postmenopausal patients taken at baseline and under tamoxifen therapy. Graphical Abstract Sample preparation and derivatization for highly sensitive quantification of estrogenic tamoxifen metabolites and steroid hormones by HPLC-MS/MS Sample preparation and derivatization for highly sensitive quantification of estrogenic tamoxifen metabolites and steroid hormones by HPLC-MS/MS
- 1 July 2003
- Published by Elsevier in Journal of Chromatography B
- Vol. 791 (1-2) , 371-380
Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography–tandem mass spectrometry
- 1 July 2003
- Published by Elsevier in Journal of Chromatography B
- Vol. 791 (1-2) , 371-380
Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography–tandem mass spectrometry
- 10 March 1998
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 357 (3) , 331-335
Ocular pharmacokinetics of verapamil in rabbits
Previously, it had been demonstrated that cataract in diabetic rats can be prevented by systemical administration of the calcium channel blocker verapamil. In addition to that, 0.125% verapamil eye drops were found to significantly reduce the intraocular pressure in ocular hypertensive human subjects. The purpose of this study was to investigate the ocular penetration and elimination of verapamil after topical administration of the drug in rabbits. Two drops of a 0.125% aqueous solution of RS-verapamil hydrochloride (corresponding to a total dose of 125 μg RS-verapamil hydrochloride) were administered into the conjunctival sac. Aqueous humor and blood samples were taken at different times after administration and analysed for drug concentration by combined gas chromatography-mass spectroscopy. Following the instillation of 0.125% verapamil eye drops in a total dose of 125 μg RS-verapamil, mean (± SEM) aqueous humor peak levels of 1607 ± 272 ng/ml were achieved after 20 min. Mean half-life for the elimination from the aqueous humor was 33 min. Topical application of verapamil produced very low serum peak concentrations (10.5 ± 1.3 ng/ml). The results of our study demonstrate that topically administered verapamil readily penetrates into the anterior chamber leading to aqueous humor drug levels in the μM range without producing serum levels that are high enough to cause cardiovascular side effects.
- 10 March 1998
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 357 (3) , 331-335
Ocular pharmacokinetics of verapamil in rabbits
Previously, it had been demonstrated that cataract in diabetic rats can be prevented by systemical administration of the calcium channel blocker verapamil. In addition to that, 0.125% verapamil eye drops were found to significantly reduce the intraocular pressure in ocular hypertensive human subjects. The purpose of this study was to investigate the ocular penetration and elimination of verapamil after topical administration of the drug in rabbits. Two drops of a 0.125% aqueous solution of RS-verapamil hydrochloride (corresponding to a total dose of 125 μg RS-verapamil hydrochloride) were administered into the conjunctival sac. Aqueous humor and blood samples were taken at different times after administration and analysed for drug concentration by combined gas chromatography-mass spectroscopy. Following the instillation of 0.125% verapamil eye drops in a total dose of 125 μg RS-verapamil, mean (± SEM) aqueous humor peak levels of 1607 ± 272 ng/ml were achieved after 20 min. Mean half-life for the elimination from the aqueous humor was 33 min. Topical application of verapamil produced very low serum peak concentrations (10.5 ± 1.3 ng/ml). The results of our study demonstrate that topically administered verapamil readily penetrates into the anterior chamber leading to aqueous humor drug levels in the μM range without producing serum levels that are high enough to cause cardiovascular side effects.
- 13 January 1995
- Published by Springer Nature in Clinical Pharmacology & Therapeutics
- Vol. 57 (1) , 52-61
Stereoselectivity in cardiovascular and biochemical action of calcium antagonists: Studies with the enantiomers of the dihydropyridine nitrendipine*
The cardiovascular and biochemical effects of R- and S-nitrendipine were studied in six healthy subjects in a single-blind placebo-controlled study. After received oral doses of placebo, 20 mg R-, 80 mg R- (n = 5), 20 mg S-, and 20 mg racemic nitrendipine, heart rate, systolic, diastolic, and mean arterial blood pressure, leg blood flow, peripheral vascular resistance, plasma renin activity, norepinephrine, epinephrine, dopamine, and aldosterone plasma levels were measured before and up to 3 hours after administration. Neither placebo nor 20 or 80 mg R-nitrendipine caused significant changes of cardiovascular and biochemical parameters. After 20 mg S-nitrendipine and 20 mg racemic nitrendipine, significant changes in diastolic blood pressure (-9.1/-7.4 mm Hg), heart rate (+21.9/+17.3 beats/min), leg blood flow (+6.8 ml.min-1.gm tissue-1), peripheral vascular resistance (-16.9 mm Hg.min.gm tissue.ml-1), norepinephrine (+476/+281 ng.L-1), and plasma renin activity (+9.5/+3.6 ng.ml-1.hr-1) were observed. The changes in cardiovascular and biochemical parameters were closely related to the serum S-nitrendipine concentrations. It can be concluded that, after administration of the racemate, the S-enantiomer is responsible for the cardiovascular and biochemical effects observed and that S-nitrendipine is at least an order of magnitude more potent than the R-enantiomer.
- 13 January 1995
- Published by Springer Nature in Clinical Pharmacology & Therapeutics
- Vol. 57 (1) , 52-61
Stereoselectivity in cardiovascular and biochemical action of calcium antagonists: Studies with the enantiomers of the dihydropyridine nitrendipine*
The cardiovascular and biochemical effects of R- and S-nitrendipine were studied in six healthy subjects in a single-blind placebo-controlled study. After received oral doses of placebo, 20 mg R-, 80 mg R- (n = 5), 20 mg S-, and 20 mg racemic nitrendipine, heart rate, systolic, diastolic, and mean arterial blood pressure, leg blood flow, peripheral vascular resistance, plasma renin activity, norepinephrine, epinephrine, dopamine, and aldosterone plasma levels were measured before and up to 3 hours after administration. Neither placebo nor 20 or 80 mg R-nitrendipine caused significant changes of cardiovascular and biochemical parameters. After 20 mg S-nitrendipine and 20 mg racemic nitrendipine, significant changes in diastolic blood pressure (-9.1/-7.4 mm Hg), heart rate (+21.9/+17.3 beats/min), leg blood flow (+6.8 ml.min-1.gm tissue-1), peripheral vascular resistance (-16.9 mm Hg.min.gm tissue.ml-1), norepinephrine (+476/+281 ng.L-1), and plasma renin activity (+9.5/+3.6 ng.ml-1.hr-1) were observed. The changes in cardiovascular and biochemical parameters were closely related to the serum S-nitrendipine concentrations. It can be concluded that, after administration of the racemate, the S-enantiomer is responsible for the cardiovascular and biochemical effects observed and that S-nitrendipine is at least an order of magnitude more potent than the R-enantiomer.
- 1 January 1993
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 32 (2) , 151-155
Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines
Modulators for the reversal of multidrug resistance such as R-verapamil and B8509-035, a dihydropyridine, effectively overcome multidrug resistance in vitro and are currently undergoing clinical trial. One problem with their use is the application protocol; the question as to whether they should be given by continuous administration or in sequential doses in combination with the cytotoxic drugs has to be addressed. Therefore, we examined the influence of the exposure time and the sequence of modulator administration on the active transport of the fluorescent dye rhodamine 123 (R123), a substrate for the P-glycoprotein, in the resistant lymphoblastid cell line VCR1000 and the parental nonresistant cell line CCRFCEM. Our results demonstrate the importance of coadministration of R-verapamil and the cytotoxic agent for the modulation of multidrug resistance, whereas the exposure sequence does not seem to be such an essential parameter in the case of B8509-035. This observation should be considered for the further design of clinical studies.
- 1 January 1993
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 32 (2) , 151-155
Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines
Modulators for the reversal of multidrug resistance such as R-verapamil and B8509-035, a dihydropyridine, effectively overcome multidrug resistance in vitro and are currently undergoing clinical trial. One problem with their use is the application protocol; the question as to whether they should be given by continuous administration or in sequential doses in combination with the cytotoxic drugs has to be addressed. Therefore, we examined the influence of the exposure time and the sequence of modulator administration on the active transport of the fluorescent dye rhodamine 123 (R123), a substrate for the P-glycoprotein, in the resistant lymphoblastid cell line VCR1000 and the parental nonresistant cell line CCRFCEM. Our results demonstrate the importance of coadministration of R-verapamil and the cytotoxic agent for the modulation of multidrug resistance, whereas the exposure sequence does not seem to be such an essential parameter in the case of B8509-035. This observation should be considered for the further design of clinical studies.
- Open Access
- 1 January 1992
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 33 (1) , 51-59
Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers.
1. The pharmacokinetics, protein binding, bioavailability and metabolism of (+)‐R‐ and (‐)‐S‐nitrendipine were studied in six healthy subjects following random oral administration of 20 mg (+)‐R‐, 20 mg (‐)‐S‐ and 20 mg R,S‐nitrendipine (pseudoracemic mixture of 10 mg [13C4)‐ (+)‐R‐ and 10 mg (‐)‐S‐enantiomer). 2. After administration of the enantiomers pronounced differences in AUC (R: 29.9 +/‐ 20.1; S: 123.8 +/‐ 63.7 ng ml‐1 h; P less than 0.05), bioavailability (R: 10.7 +/‐ 7.4%; S: 44.6 +/‐ 23.1%; P less than 0.05) and Cmax (R: 14.4 +/‐ 7.7; S: 72.5 +/‐ 40.5 ng ml‐1; P less than 0.05) were observed between R‐ and S‐nitrendipine. When racemic nitrendipine was given bioavailability and dose normalized AUC and Cmax values of the S‐enantiomer were not different from the values after S‐nitrendipine‐administration. In contrast, bioavailability (R: 10.7% R,S: 22.1%) and dose normalized AUC (R: 15.0; R,S: 29.5 ng ml‐1 h and Cmax (R: 7.2; R,S: 16.8 ng ml‐1) of R‐ nitrendipine were doubled following R,S‐ as compared with R‐ nitrendipine administration. t1/2 (R: 9.8; S: 9.1 h) and tmax were not different between the enantiomers nor were the values different after administration of the enantiomers or racemate. The fraction unbound in serum of R‐nitrendipine was 0.0098 +/‐ 0.0032 (s.d.) and that of S‐ nitrendipine was 0.0083 +/‐ 0.0015 (s.d.). 3. The AUC values of the major pyridine metabolite M1 were similar after administration of R‐ and S‐nitrendipine (S: 114.7 +/‐ 48.5; R: 71.7 +/‐ 29.9 ng ml‐1 h).(ABSTRACT TRUNCATED AT 250 WORDS)
- 1 January 1992
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 33 (1) , 51-59
Open AccessUse of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers.
1. The pharmacokinetics, protein binding, bioavailability and metabolism of (+)‐R‐ and (‐)‐S‐nitrendipine were studied in six healthy subjects following random oral administration of 20 mg (+)‐R‐, 20 mg (‐)‐S‐ and 20 mg R,S‐nitrendipine (pseudoracemic mixture of 10 mg [13C4)‐ (+)‐R‐ and 10 mg (‐)‐S‐enantiomer). 2. After administration of the enantiomers pronounced differences in AUC (R: 29.9 +/‐ 20.1; S: 123.8 +/‐ 63.7 ng ml‐1 h; P less than 0.05), bioavailability (R: 10.7 +/‐ 7.4%; S: 44.6 +/‐ 23.1%; P less than 0.05) and Cmax (R: 14.4 +/‐ 7.7; S: 72.5 +/‐ 40.5 ng ml‐1; P less than 0.05) were observed between R‐ and S‐nitrendipine. When racemic nitrendipine was given bioavailability and dose normalized AUC and Cmax values of the S‐enantiomer were not different from the values after S‐nitrendipine‐administration. In contrast, bioavailability (R: 10.7% R,S: 22.1%) and dose normalized AUC (R: 15.0; R,S: 29.5 ng ml‐1 h and Cmax (R: 7.2; R,S: 16.8 ng ml‐1) of R‐ nitrendipine were doubled following R,S‐ as compared with R‐ nitrendipine administration. t1/2 (R: 9.8; S: 9.1 h) and tmax were not different between the enantiomers nor were the values different after administration of the enantiomers or racemate. The fraction unbound in serum of R‐nitrendipine was 0.0098 +/‐ 0.0032 (s.d.) and that of S‐ nitrendipine was 0.0083 +/‐ 0.0015 (s.d.). 3. The AUC values of the major pyridine metabolite M1 were similar after administration of R‐ and S‐nitrendipine (S: 114.7 +/‐ 48.5; R: 71.7 +/‐ 29.9 ng ml‐1 h).(ABSTRACT TRUNCATED AT 250 WORDS)
- 1 October 1991
- Published by Elsevier in Biochemical Pharmacology
- Vol. 42 (10) , R13-R16
Identification of the “major” polymorphic carbocysteine metabolite as S-(carboxymethylthio)-l-cysteine
- 1 October 1991
- Published by Elsevier in Biochemical Pharmacology
- Vol. 42 (10) , R13-R16
Identification of the “major” polymorphic carbocysteine metabolite as S-(carboxymethylthio)-l-cysteine
- Open Access
- 1 March 1991
- Published by Wiley
- Vol. 31 (3) , 313-322
Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.
1. The pharmacokinetics, bioavailability, metabolism and antihypertensive effects of nitrendipine have been studied in 12 patients with impaired renal function and moderate to severe hypertension. The drug was administered simultaneously by the i.v. [13C4] and oral (commercial tablet 20 mg) routes. 2. No differences in the pharmacokinetic parameters were observed between the two routes of administration. The systemic clearance after i.v. administration in patients with renal impairment (18.2 +/- 6.1 ml min-1 kg-1) was similar to that observed in healthy volunteers. Despite complete absorption of drug from the tablet the bioavailability of the parent compound was 21.2 +/- 12.5%. Cumulative urinary excretion of nitrendipine metabolites was correlated with the creatinine clearance (r = 0.946). 3. Significant reductions in mean arterial blood pressure (mean: 23.6%) at the end of the nitrendipine infusion and after oral administration of 20 mg (mean: 17.5%) were observed. The blood pressure lowering effect of nitrendipine could be correlated within individuals with serum nitrendipine concentrations using a log linear model. 4. Following 4 weeks of therapy an average dose of 77 mg nitrendipine day- 1 was required to achieve a systolic blood pressure below 160 mm Hg or a diastolic blood pressure below 90 mm Hg. The reduction in blood pressure during multiple dosing was related to the nitrendipine steady- state concentration. There was a significant relationship between the nitrendipine bioavailability and the dose required for sufficient blood pressure control. 5. No accumulation of nitrendipine caused by impaired renal function was observed during multiple dosing. Thus, no reduction of the nitrendipine dose in patients with renal impairment is necessary.
- 1 March 1991
- Published by Wiley
- Vol. 31 (3) , 313-322
Open AccessPharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.
1. The pharmacokinetics, bioavailability, metabolism and antihypertensive effects of nitrendipine have been studied in 12 patients with impaired renal function and moderate to severe hypertension. The drug was administered simultaneously by the i.v. [13C4] and oral (commercial tablet 20 mg) routes. 2. No differences in the pharmacokinetic parameters were observed between the two routes of administration. The systemic clearance after i.v. administration in patients with renal impairment (18.2 +/- 6.1 ml min-1 kg-1) was similar to that observed in healthy volunteers. Despite complete absorption of drug from the tablet the bioavailability of the parent compound was 21.2 +/- 12.5%. Cumulative urinary excretion of nitrendipine metabolites was correlated with the creatinine clearance (r = 0.946). 3. Significant reductions in mean arterial blood pressure (mean: 23.6%) at the end of the nitrendipine infusion and after oral administration of 20 mg (mean: 17.5%) were observed. The blood pressure lowering effect of nitrendipine could be correlated within individuals with serum nitrendipine concentrations using a log linear model. 4. Following 4 weeks of therapy an average dose of 77 mg nitrendipine day- 1 was required to achieve a systolic blood pressure below 160 mm Hg or a diastolic blood pressure below 90 mm Hg. The reduction in blood pressure during multiple dosing was related to the nitrendipine steady- state concentration. There was a significant relationship between the nitrendipine bioavailability and the dose required for sufficient blood pressure control. 5. No accumulation of nitrendipine caused by impaired renal function was observed during multiple dosing. Thus, no reduction of the nitrendipine dose in patients with renal impairment is necessary.